GE Healthcare, a leading U.S. medical device manufacturer, is reportedly evaluating strategic options for its China operations, including a potential outright sale or partnership. According to a confidential source, the company is working with advisors to explore these possibilities, though discussions remain in the early stages. The China unit, which produces CT and MRI scanners among other devices, could be valued in the billions of dollars, though precise figures are yet to be determined. Bloomberg first reported the news, citing sources familiar with the matter. GE Healthcare, with a market value of approximately $34 billion, has not officially commented on the potential sale. A spokesperson reiterated the company’s commitment to supporting Chinese patients but declined to address market rumors. The China unit operates six manufacturing bases but faced a 15% revenue decline in 2024, attributed to tariffs and economic challenges. GE Healthcare’s CFO previously indicated plans to shift production to more tariff-friendly regions. The move reflects broader concerns among U.S. companies operating in China, where political tensions, domestic competition, and slowing economic growth have dampened confidence. A recent survey by the American Chamber of Commerce in Shanghai revealed that only 41% of U.S. firms are optimistic about their five-year business outlook in China, the lowest level since the survey began in 1999. This development follows similar actions by other U.S. companies, such as Bristol Myers Squibb, which recently sold its stake in a Chinese pharmaceutical joint venture.